FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.
What happened
FDA reviewed the company's website https://primepeptides.co in October 2024, plus its Facebook, Instagram and YouTube pages, which point buyers to the site. FDA found pages and posts saying the products lower blood sugar, treat type 2 diabetes, cut cardiovascular events and cause large weight loss, even though the labels say "research purposes only" and "not for human consumption." FDA concluded the products are drugs for human use sold without an approved application, which is illegal.
What FDA found
The company sells Semaglutide and Retatrutide as drugs without an FDA-approved application, which the law requires before a new drug can be sold across state lines.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)Website and social media claims that the products treat diabetes, obesity and heart risk show they are intended as drugs for human use, despite the "research purposes only" label.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The products are "new drugs" because they are not generally recognized as safe and effective for the uses claimed on the site.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)The "not for human consumption" labeling is contradicted by weight-loss testimonials, customer reviews and videos telling people the products are safe and effective.
Social media posts, including customer reviews calling the products "Safe & Effective," promote the unapproved products for human use and direct consumers to the website to buy them.
What FDA wants
FDA asks the company to write back within fifteen working days describing the specific steps taken to fix the violations and prevent them from happening again, with supporting documents. If the company believes its products are lawful, it must send its reasoning and evidence.
Who should pay attention
- online sellers of peptides labeled "research use only"
- telehealth and compounding operations offering GLP-1 products
- brands and clinics sourcing semaglutide or retatrutide from unapproved suppliers
This is a summary. Read the original letter on fda.gov.